肝脏 ›› 2025, Vol. 30 ›› Issue (1): 21-23.

• 药物性肝损伤 • 上一篇    下一篇

儿童药物性肝损伤不良反应发生的临床特点及其规律

杨慧敏, 彭琪, 赵媛   

  1. 610100 四川 成都市龙泉驿区妇幼保健院儿内科(杨慧敏);空军军医大学第一附属医院药剂科(彭琪);西安存济医学中心药剂科(赵媛)
  • 收稿日期:2023-12-10 出版日期:2025-01-31 发布日期:2025-03-10
  • 通讯作者: 彭琪,Email:xiaoxi171215@163.com
  • 基金资助:
    四川省科技计划重点研发项目(2020YFS0484)

The clinical characteristics and regularity of adverse reactions of drug-induced liver injury in children

YANG Hui-min, PENG Qi, ZHAO Yuan   

  1. 1. Department of Pediatrics, Longquanyi District Maternal and Child Health Hospital, Chengdu, Sichuan 610100, China;
    2. Department of Pharmacy, First Affiliated Hospital of Air Force Military Medical University, Xi'an 710032, China;
    3. Department of Pharmacy, Xi'an Cunji Medical Center, Shaanxi 710000, China
  • Received:2023-12-10 Online:2025-01-31 Published:2025-03-10
  • Contact: PENG Qi,Email:xiaoxi171215@163.com

摘要: 目的 探讨儿童药物性肝损伤(DILI)不良反应发生的临床特征及其规律。 方法 纳入2020年1月至2022年12月我院收治的儿童DILI患者114例,收集DILI患者临床资料,包括性别、年龄、基础疾病史、用药时间、药物种类、给药方式、临床表现、治疗结局等,总结发生的临床特点及其规律。 结果 114例患者中,男性33例,女性36例;13~18岁69例(60.5%),≤1岁10例(8.8%)。呼吸道感染31例(27.2%),有临床症状99例(86.8%),无明显症状15例(13.2%),临床症状依次表现为食欲减退、乏力、发热、呕吐、黄疸、皮疹、恶心及腹胀。肝细胞损伤型97例(85.1%)、胆汁淤积性6例(5.3%)、混合型11例(9.6%)。肝损伤患者血清AST为(531.7±149.6)U/L,高于其他两组的(296.1±105.5)U/L和(167.9±72.8)U/L;血清ALT为(765.6±217.5)U/L,高于其他两组的(123.4±79.1)U/L和(358.2±104.7)U/L;血清ALP为(330.4±187.5)U/L,高于其他两组的(301.2±101.3)U/L和(198.3±171.6)U/L,差异均有统计学意义(均P<0.05)。65例(74.1%)好转、32例(28.1)治愈、4例(3.5%)未愈、13例(11.5%)临床结局不详。引起儿童DILI的药物类别依次为:抗菌药(26.7%)、中药(21.6%)、解热镇痛药(18.8%)、肿瘤化疗药(11.9%)、抗结核药(10.2%)、精神疾病药(5.7%)、抗病毒药(2.8%)及激素(2.27%)。其中93例(52.8%)为口服给药,占比最多,发病时间为(30.2±8.9)d;最少为皮下注射1例(0.5%),发病时间为(20.0±0.0)d。 结论 临床医师对于儿童用药应该慎重,从儿童自身因素、药物因素及临床特点分析,保障儿童用药安全。

关键词: 药物性肝损伤, 临床特征, 儿童, 合理用药

Abstract: Objective To investigate the clinical characteristics and regularity of adverse reactions in children with drug-induced liver injury (DILI), and to provide a theoretical reference for the safe and rational use of drugs by clinical pediatricians. Methods The clinical data of 114 children with DILI admitted to our hospital from January 2020~December 2022 were collected, including gender, age, history of underlying diseases, medication time, drug type, mode of administration, clinical manifestations, treatment outcomes, etc., and the clinical characteristics and regularities of DILI occurrence were summarized. Methods Among the 114 patients, 69 (60.5%) were 13~18 years old, with 33 males and 36 females, accounting for the largest proportion. 10 cases (8.8%) that were ≤ 1 year of age accounted for the lowest proportion. Respiratory tract infection affected 31 cases (27.2%) was the most common underlying disease. Ninety-nine cases (86.8%) had clinical symptoms and 15 cases (13.2%) had no obvious symptoms. The clinical symptoms included decreased appetite, fatigue, fever, vomiting, jaundice, rash, nausea and abdominal distention; Among the 114 patients, there were 97 cases (85.1%) of hepatocellular injury type, 6 cases (5.3%) of cholestatic type, and 11 cases (9.6%) of mixed type. The serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels of patients with hepatocellular injury was (531.7±149.6) U/L, (765.6±217.5) U/L, and (330.4±187.5) U/L, respectively, which was significantly higher than those of cholestatic type [(296.1±105.5) U/L, (123.4±79.1) and (301.2±101.3) U/L, respectively] and those of mixed type [(167.9±72.8) U/L, (358.2±104.7) U/L, and (198.3±171.6)U/L, respectively]( All P<0.05). Among the 114 patients, 65 (74.1%) patients improved, 32 (28.1%) patients were cured, 4 (3.5%) patients were uncured, and 13 (11.5%) patients had unknown clinical outcomes. The drug categories that caused DILI in children were antibacterial drugs (26.7%), traditional Chinese medicines (21.6%), antipyretic analgesics (18.8%), tumor chemotherapy drugs (11.9%), anti-tuberculosis drugs (10.2%), psychiatric drugs (5.7%), antivirals (2.8%) and hormones (2.27%). The causal drugs were administered orally in ninety-three cases (52.8%), accounting for the largest proportion, and the number of onset days was (30.2±8.9) days; The minimum proportion was 1 case (0.5%) who was administered by subcutaneous injection, and the number of onset days was (20.0±0.0) days. Conclusion Clinicians should be cautious about the use of drugs in children. Children's own factors, drug factors and clinical characteristics should all be considered. Active drug publicity and regular testing are necessary for the prevention, early diagnosis and treatment of DILI in children, and to ensure the safety of children's medication.

Key words: Drug-induced liver injury, Clinical features, Child, Rational use of medicines